US applies least burdensome criteria to PMS (premarket submission) guidance
This article was originally published in Clinica
Executive Summary
The US FDA has decided to apply its least burdensome litmus test for rulemaking to a long-awaited guidance on when companies have to file a new premarket submission (PMS) to make an additional claim for their product.